Saturday, 3 October 2026European Markets

Energy Security

3 articles

Nine Weeks of Hormuz Closure Risks 1970s-Scale Energy Shock for Europe

Nine Weeks of Hormuz Closure Risks 1970s-Scale Energy Shock for Europe

The Strait of Hormuz closure is entering its ninth week following a US-Israel military strike on Iran, with economists comparing the shock to the 1970s oil crises. Stagflation risks are mounting as demand destruction spreads from Asian markets into Western economies. European policymakers face constrained options as inflation pressure collides with already-fragile growth.

LM Salvado•
Economists Warn Middle East Conflict Could Trigger 1970s-Style Oil Shock for Europe

Economists Warn Middle East Conflict Could Trigger 1970s-Style Oil Shock for Europe

A Middle East conflict threatening the Strait of Hormuz has drawn warnings from top economists of an energy crisis rivalling the 1970s. IMF chief economist Pierre-Olivier Gourinchas says the shock could drive unemployment and food insecurity across multiple countries. Without a resolution, economist Justin Wolfers warns elevated energy costs could persist for years — a direct threat to Europe's energy-dependent economy.

LM Salvado•
Hormuz blockade removes 20M barrels daily, pushing UK mortgage rates up as inflation delays easing until 2026

Hormuz blockade removes 20M barrels daily, pushing UK mortgage rates up as inflation delays easing until 2026

The Middle East conflict has cut 20 million barrels per day from global oil markets through a Hormuz Strait blockade, according to MacroEdge Research. Resulting inflationary pressure is forcing the Bank of England to hold rates at 3.75% while UK mortgage lenders raise borrowing costs, with Federal Reserve officials warning price pressures won't ease before late 2026.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com